Pneumocystis jirovecii pneumonia
Conditions
Interventions
Observational group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >=18 year; 2.Imaging, microbiological, and/or molecular biological results indicating Pneumocystis jirovecii Pneumonia; 3.Previously treated with oral trimethoprim-sulfamethoxazole (SMZ-TMP) tablets but intolerant due to gastrointestinal adverse reactions and intended to switch to SMZ-TMP injection; 4.Willing to undergo therapeutic drug monitoring (TDM) of sulfamethoxazole/trimethoprim; 5.Voluntarily participate in this study, with the patient or their legal representative fully informed and having signed the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Duration of trimethoprim-sulfamethoxazole (SMZ-TMP) injection use < 7 days; 2.Positive pregnancy test or currently breastfeeding; 3.Patients from whom blood samples cannot be obtained;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The clinical efficacy of intravenous compound sulfamethoxazole at the end of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality;Safety endpoints (any adverse reactions and laboratory findings, including nephrotoxicity, hepatotoxicity, etc.);PK/PD targets for sulfamethoxazole and trimethoprim; | — |
Countries
China
Contacts
Public ContactZhang Chunhong
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed